Source: Minerva Studio / Shutterstock.com
ZyVersa Therapeutics (NASDAQ:ZVSA) The stock is rising on Wednesday after the clinical-stage biopharmaceutical company highlighted the publication of an article in a peer-reviewed journal.
This paper, titled “NLRP3 and AIM2 hematopoietic inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” was published in diabetes. It involves studying type 1 diabetes and atherosclerosis in mice.
According to a press release from ZyVersa Therapeutics, this paper shows increased levels of cleaved caspase-1 in peritoneal fluid when inflammasome signaling pathways are activated. They also showed similar plasma IL-1β and IL-18 levels as well as sizes and severity of aortic lesions.
The article also suggests that activation of the NLRP3 and AIM2 inflammasome contributes to the development of atherosclerotic lesions. These are similar results to other animal studies.
Stephen Glover, co-founder, chairman, president and CEO of ZyVersa Therapeutics, had this to say about the news.
“ZyVersa’s inflammasome ASC inhibitor IC 100 is designed to inhibit the formation of multiple types of inflammasomes and their associated ASC patches to attenuate the development and maintenance of harmful inflammation that contributes to numerous diseases.”
ZVSA stock movement today
Today’s news is accompanied by brisk trading in ZVSA shares. At the time of this writing, approximately 6 million shares were changing hands. For comparison, the stock’s daily average trading volume is approximately 223,000 shares.
ZVSA shares have risen 27.2% since Wednesday morning.
Investors who want to learn more about the latest stock market news today are in luck!
We have all the important stock market stories worth reading about on Wednesday! This also includes what happens to you Apple (NASDAQ:AAPL), Plug-in power supply (NASDAQ:PLUG) And Carbon revolution (NASDAQ:CREV) Inventory today. All news can be found under the following links!
More stock market news from Wednesday
At the time of publication: William White did not have, directly or indirectly, any positions in the securities mentioned in this article. The opinions expressed in this article are those of the author, subject to those of InvestorPlace.com Publishing Guidelines.
With only the rarest of exceptions, InvestorPlace does not publish commentary on companies that have a market capitalization of less than $100 million or trade fewer than 100,000 shares per day. Because these “penny stocks” are often a playground for fraudsters and market manipulators. If we ever post a comment on a low volume stock that may be affected by our comment, we require itInvestorPlace.comThe authors disclose this fact and warn readers about the risks.
Read more: Penny Stocks — This is how you benefit without being cheated